A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01).

Soran, Atilla; Özmen, Vahit; Özbaş, Serdar; Karanlık, Hasan; Müslümanoğlu, Mahmut; İğci, Abdullah; Cantürk, Zafer; Utkan, Zafer; Özaslan, Cihangir; Evrensel, Türkkan; Uras, Cihan; Aksaz, Erol; Soyder, Aykut; Uğurlu, Ümit; Çöl, Cavit; Cabıoğlu, Neslihan; Bozkurt, Betül; Sezgın, Efe; Johnson, R. R.; Lembersky, Barry C.

doi:10.1200/jco.2016.34.15_suppl.1005

Cited by 59 publications

(51 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far only two small studies have been published/presented [19, 20]. A subgroup analysis of the Turkish study suggested a potential benefit in patients with ER/PgR+, HER-2 negative, solitary bone metastasis, who are younger than 55 years of age, while patients with multiple pulmonary and liver metastasis did worse with an overall 3-year survival of 31% in the surgery group versus 67% for the systemic therapy group [20]. In the Indian trial, a decrease in distant progression-free survival was observed in patients allocated to surgery.…”

Section: General Recommendationsmentioning

confidence: 99%

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Cardoso¹,

et al. 2017

View full text Add to dashboard Cite

Section: General Recommendationsmentioning

confidence: 99%

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Cardoso¹,

et al. 2017

View full text Add to dashboard Cite

“…Although in the Turkish MF07-01 trial median overall survival was improved by a nonsignificant 4 months (from 46 months in the surgery group and 42 months in the group receiving systemic treatment only), overall survival was 18 months in both groups in the Indian study. 42,43 As a note of caution, the Indian study included only patients responding to anthracycline or taxane chemotherapy, and 10% in the no-surgery arm received palliative surgery of the primary tumor. Moreover, a median overall survival of 18 months is low.…”

Section: Discussionmentioning

confidence: 99%

Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer

et al. 2016

View full text Add to dashboard Cite

The present study-the first population-based analysis using propensity score methods-provides evidence of a favorable impact of primary tumor surgery on mortality in metastatic breast cancer patients. Most importantly, the benefit of primary tumor surgery increased over time from 1998 to 2009. Although the final results of ongoing randomized studies are awaited, currently available evidence should be discussed with metastatic breast cancer patients.

show abstract

“…For this purpose, prospective multicenter clinical trials and genomic/molecular studies should be included within the second group of research projects. The multicenter clinical study designed by TMDFH entitled ''Effectiveness of surgery in patients with metastatic breast cancer'' is the first of its kind in the world, which poses a very valuable example in this regard (17). This study investigated whether surgery offers benefit to patients diagnosed as having metastatic disease; the 3-year follow-up results will be published next year.…”

Section: Project Suggestionsmentioning

confidence: 99%

Turkish Ministry of Health, 2nd Turkish Medical General Assembly Clinical Oncology Study Group Report

Özmen

Dağoğlu

Dede³

et al. 2016

J Breasth Health

Self Cite

View full text Add to dashboard Cite

Objective: There is an increase in the incidence of cancer, and consequently in mortality rates, both in the world and in Turkey. The increase in the incidence and mortality rate of cancer are more prominent in our country as well as in other developing countries. The aim of this workshop was to determine the current status on prevention, screening, early diagnosis and treatment of cancer in our country, to identify related shortcomings, specify solutions and to share these with health system operators, and to aid in implementation of these systems. Developments on palliative care were also evaluated. Materials and Methods: The current situation in the practice of clinical oncology, related drawbacks, problems encountered during multidisciplinary approach and their solutions were discussed under several sub-headings during a 3-day meeting organized by the Turkish Ministry of Health (Türkiye Cumhuriyeti Sağlık Bakanlığı-TCSB) with participation of 16 scientists from Turkey and 6 from abroad, and the conclusions were reported. Results: It is expected that the newly established Turkish Health Institutes Association (Türkiye Sağlık Enstitüleri Başkanlığı-TÜSEB) and the National Cancer Institute (Ulusal Kanser Enstitüsü) will provide a new framework in the field of oncology. The current positive findings include the increase in the number of scientists who carry out successful trials in oncology both in Turkey and abroad, the implementation of the national cancer registry program by the Cancer Control Department and the breast cancer registry program by the Turkish Federation of Breast Diseases Societies (Türkiye Meme Hastalıkları Dernekleri Federasyonu-TMHDF), and introduction of Cancer Early Diagnosis, Screening, and Training Centers (Kanser Erken Tanı, Tarama ve Eğitim Merkezi-KETEM) for the application of community-based cancer screening programs. In addition to these, obvious shortcomings related to education, implementation, management and research issues were also determined, and policy and project proposals to address these issues were presented. Collaboration with relevant organizations in the implementation of these studies was supported. Conclusion: Both the incidence and mortality rates of cancer are increasing in Turkey. The widespread deficiencies in population-based screening and in effective treatment lead to an increase in delay in diagnosis and mortality. Despite improvements in data recording, screening and treatment over the last 10 years, extensive, organized, population-based screening programs and fully equipped early diagnosis and treatment centers are required. Enhancement of basic cancer epidemiologic, translational, genetic and molecular research studies is essential in our country. Improvements on pain treatment and palliative care of patients with chronic and terminal cancer are also required.

show abstract

A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01).

Cited by 59 publications

References 0 publications

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer

Turkish Ministry of Health, 2nd Turkish Medical General Assembly Clinical Oncology Study Group Report

Contact Info

Product

Resources

About